Published in Hum Vaccin Immunother on January 01, 2014
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | NCT01629758
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | NCT01975831
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. J Natl Cancer Inst (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Thymus-marrow cell combinations. Synergism in antibody production. Proc Soc Exp Biol Med (1966) 10.03
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer (2014) 2.27
The new B7s: playing a pivotal role in tumor immunity. J Immunother (2007) 2.15
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol (2009) 2.04
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol (2013) 1.86
Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol (2010) 1.84
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer (2013) 1.35
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Lineage relationship of effector and memory T cells. Curr Opin Immunol (2013) 1.30
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2012) 1.19
Cancer immunotherapy. Mol Oncol (2012) 1.13
Chemoimmunotherapy. Cancer J (2010) 1.13
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014) 1.13
Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes. Int J Cancer (1982) 1.09
Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med (2012) 1.04
Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol (2014) 0.94
Therapeutic vaccines: the ultimate personalized therapy? Hum Vaccin Immunother (2012) 0.94
The biochemistry and cell biology of antigen presentation by MHC class I and class II molecules. Implications for development of combination vaccines. Ann N Y Acad Sci (1995) 0.90
Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs (2008) 0.87
Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines (2014) 0.86
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology (2014) 0.84
Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. J Clin Invest (2003) 0.81
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Cancer vaccines: moving beyond current paradigms. Clin Cancer Res (2007) 2.40
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci (2007) 1.89
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) (2008) 1.38
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Costimulatory molecules as adjuvants for immunotherapy. Front Biosci (2006) 1.37
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther (2006) 1.33
A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int (2005) 1.33
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res (2010) 1.30
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood (2012) 1.30
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother (2010) 1.17
Paradigm shifts in cancer vaccine therapy. Exp Biol Med (Maywood) (2008) 1.13
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014) 1.13
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol (2009) 1.11
Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol (2012) 1.09
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol (2007) 1.07
Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther (2009) 1.03
A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer (2006) 1.02
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. J Immunol (2013) 1.01
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther (2010) 0.99
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother (2013) 0.98
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med (2012) 0.98
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother (2011) 0.97
PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther (2007) 0.97
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin Cancer Res (2005) 0.96
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int (2007) 0.95
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2011) 0.94
Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol (2014) 0.94
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol (2009) 0.93
Serum antibodies to blood group A predict survival on PROSTVAC-VF. Clin Cancer Res (2013) 0.92
Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proc Natl Acad Sci U S A (2014) 0.91
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. J Biomed Biotechnol (2010) 0.90
Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther (2003) 0.90
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. Cancer Immunol Immunother (2013) 0.90
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunol Immunother (2009) 0.88
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer (2010) 0.88
PSA-based vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2006) 0.88
Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther (2012) 0.88
The role of soluble CD40L in immunosuppression. Oncoimmunology (2013) 0.88
TRICOM vector based cancer vaccines. Curr Pharm Des (2006) 0.87
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J Urol (2010) 0.86
Therapeutic vaccines for prostate cancer. Oncologist (2006) 0.86
Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci (2010) 0.85
Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol (2014) 0.85
The use of bisphosphonates in cancer patients. Acta Oncol (2007) 0.85
Hepcidin, anaemia, and prostate cancer. BJU Int (2011) 0.85
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. Clin Genitourin Cancer (2007) 0.85
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). Int J Cancer (2007) 0.84
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. Int J Cancer (2013) 0.84
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 0.83
The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer (2010) 0.83
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer (2004) 0.83
Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. J Natl Compr Canc Netw (2012) 0.83
Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. Am J Ther (2010) 0.82
Combining Vaccines with Conventional Therapies for Cancer. Update Cancer Ther (2007) 0.82
Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer. Expert Rev Vaccines (2003) 0.81
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. Oncoimmunology (2012) 0.81
Novel therapeutic strategies in prostate cancer. Cancer Biol Ther (2004) 0.81
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Rev Vaccines (2011) 0.80
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. Oncologist (2013) 0.79
Ipilimumab in prostate cancer. Expert Opin Biol Ther (2012) 0.79
Immunotherapy for prostate cancer: what's the future? Hematol Oncol Clin North Am (2006) 0.79
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. BJU Int (2006) 0.79
Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. Clin Genitourin Cancer (2011) 0.78
Cancer vaccines: current directions and perspectives in prostate cancer. Curr Opin Mol Ther (2009) 0.78
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. Clin Genitourin Cancer (2013) 0.78
A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy. Clin Genitourin Cancer (2006) 0.77
A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. J Immunol Methods (2003) 0.77
Therapeutic prostate cancer vaccines: a review of the latest developments. Curr Opin Investig Drugs (2008) 0.77
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer. Rev Urol (2003) 0.77
Therapeutic vaccines for prostate cancer: a review of clinical data. Curr Opin Investig Drugs (2005) 0.77
Immunologic monitoring of cellular immune responses in cancer vaccine therapy. J Biomed Biotechnol (2011) 0.76
A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors. Clin Colorectal Cancer (2006) 0.75
Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer. Cancers (Basel) (2012) 0.75